(Feb 12): Sanofi abruptly replaced chief executive officer Paul Hudson after a massive research spending boost failed to deliver rapid results, appointing Merck KGaA’s Belén Garijo to succeed him. “Investors remain frustrated with the repeated R&D (research and development) failures,” said Abhishek Raval, an analyst at AlphaValue. Garijo’s term at Merck was ending soon and the Spanish executive knows Sanofi well, having spent 15 years there. Her priority will be to strengthen the productivity, governance, and innovation capacity of R&D, it added. “If you’d have asked me back in 2020, will it take between five and seven years for Sanofi?

Source: The Edge Markets February 12, 2026 09:50 UTC